Affimed (AFMD) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Affimed (AFMD) Misses Q4 EPS by 1c

Affimed Reports Financial Results for Fourth Quarter and Year End 2015

March 30, 2016 7:30 AM EDT

HEIDELBERG, Germany, March 30, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2015.

"2015 was a formative year for Affimed," said Dr. Adi Hoess, CEO of Affimed. "Through the continuous support of our investors we were able to broaden the development of our NK- and T-cell-recruiting immunotherapies. We have continued to successfully advance our clinical and preclinical pipeline and, in particular, we have made significant headway with our lead... More